NovoCure Q3 Revenue Up 16% to $193.4M; Adjusted EBITDA Turns Positive at $15.7M
NVCR sits 45% above its 52-week low of $9.82.
Summary
NovoCure grew Q3 revenue 16% to $193.4M, expanded gross margin to 77%, and turned Adjusted EBITDA positive at $15.7M while narrowing its net loss to $10.4M.
Key Events · Earnings and Guidance · NVCR
-
Q3 Revenue Grows 16% to $193.4M
Net revenues rose to $193.4M from $167.2M in Q3 2025, driven by 19% global active patient growth to 5,260 patients, including 276 on Optune Pax and 255 on Optune Lua.
-
Adjusted EBITDA Turns Positive
Adjusted EBITDA was a $15.7M gain versus a $3.0M loss a year earlier, as flat cost of revenues lifted gross margin to 77% from 73% and gross profit rose $26.4M.
-
Net Loss Narrows to $10.4M
Q3 net loss fell to $10.4M ($0.09 per share) from $37.3M ($0.33); the nine-month loss of $97.2M includes a $43.4M non-cash PSU charge tied to the February Optune Pax approval.
-
Cash Position $463.5M, Runway 12+ Months
Cash, cash equivalents and short-term investments totaled $463.5M at September 30, 2026, up $15.8M from December 31, 2025, with nine-month operating cash flow positive at $17.3M.
Analysis · NVCR · Industrial Applications And Services
The operating leverage story is finally showing up in the numbers. Revenue grew 16% to $193.4M while cost of revenues stayed flat, lifting gross margin to 77% from 73% and swinging Adjusted EBITDA to a $15.7M gain from a $3.0M loss a year ago. Net loss narrowed to $10.4M from $37.3M. Nine-month operating cash flow flipped positive at $17.3M provided versus $31.0M used in the prior-year period, and the $463.5M cash and investment balance funds at least the next 12 months. Two caveats temper the picture: the nine-month GAAP loss of $97.2M still includes a $43.4M non-cash PSU charge tied to the February Optune Pax approval, and the company has forfeited Tranche C and D of its credit facility, so future funding would come from the equity market if spending outpaces gross profit.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NVCR was trading at $14.25 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $9.82 to $21.45. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.